|Bid||40.72 x 2000|
|Ask||41.74 x 2000|
|Day's Range||41.33 - 41.58|
|52 Week Range||31.86 - 41.58|
|PE Ratio (TTM)||57.16|
|Expense Ratio (net)||0.57%|
The traditional financial advisor rarely takes on new clients with a nest egg smaller than $100,000. But some now offer a low-minimum strategy.
Marriott is now trading at a forward EV-to-EBITDA multiple of 15.5x, compared with its average historical valuation of 13.9x since January 2008.
Marriott (MAR) has entered into a joint venture agreement with China’s Alibaba Group (BABA) with an aim to provide a seamless travel experience in China.
Total debt on Marriott’s balance sheet increased from $3.8 billion at the end of 2014 to $4.1 billion at the end of 2015 and $8.2 billion at the end of 4Q16.
Priceline has been funding some of its acquisitions through debt. Total debt on its balance sheet has risen from $3.9 billion at the end of 2014 to 6.2 billion at the end of 2015.
Bristol-Myers Squibb (BMY) reported 12% growth in its top line to ~$4.93 billion during 1Q17 due to 13% operational growth in its revenues
Eli Lilly's (LLY) Human Pharmaceuticals segment also consists of the oncology franchise. Key drugs in this franchise include Alimta, Erbitux, Cyramza, and Portrazza.
With the strong performance of Opdivo, Bristol-Myers Squibb's (BMY) oncology segment emerged as its largest revenue contributor in 4Q16.